Intelligence · Clinical Development
Pipeline search results
Programs matching “Astra” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 467 pipeline programs matching "Astra" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
CAAA617A12202
Novartis Pharmaceuticals
Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) with moderate and severe renal impairment and with normal renal function.
1 trial -
CAAA617B12203
Novartis Pharmaceuticals
PSMA PET scan positive Castration-Resistant Prostate Cancer (CRPC)
1 trial -
CAAA802A12101
Novartis Pharmaceuticals
PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC) and metastatic Castration-resistant Prostate Cancer (mCRPC) with or without prior 177Lu-PSMA radioligand therapy.
1 trial -
CDZR123A02101
Novartis Pharmaceuticals
advanced, solid, relapsed tumors / advanced tumors: human lymphomas / solid human tumor indications (urothelial carcinoma, or other advanced/metastatic solid tumors, ovarian clear cell cancer, endometrial carcinoma, lymphoma including peripheral T-cell Lymphoma and GCBDLBCL, malignant pleural or peritoneal mesothelioma, metastatic castration - resistant prostate cancer (mCRPC))
1 trial -
CDZR123A12107
Novartis Pharmaceuticals
Metastatic castrate resistant prostate cancer (mCRPC)
1 trial -
CJSB462B12201
Novartis Pharmaceuticals
Metastatic castration resistant prostate cancer (mCRPC)
1 trial -
CLARITY-PT01
AstraZeneca AB
Gastric Cancer, Gastroesophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
1 trial -
CO45813
Hoffmann-La Roche
Metastatic Castration-Resistant Prostate Cancer
1 trial -
CYCAD-1(D8470C00001)
AstraZeneca AB
Patients with ER+ HER2- advanced breast cancer and patients with high-grade serious ovarian cancer (HGSOC)
1 trial -
Calquence 100 mg film-coated tablets
AstraZeneca
mantle cell lymphoma (MCL)
1 trial -
Chinese Herb Astragalus membranaceus
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Stroke
1 trial -
D361FC00001
AstraZeneca AB
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
1 trial -
D4190C00022
AstraZeneca AB
Hepatocellular Carcinoma
1 trial -
D419EC00001
AstraZeneca AB
Advanced Solid Tumors
1 trial -
D4880C00003
AstraZeneca AB
unresectable pleural or peritoneal malignant mesothelioma
1 trial -
D5162C00048
AstraZeneca AB
Non-Small Cell Lung Cancer
1 trial -
D516AC00003
AstraZeneca AB
Unresectable Non-small Cell Lung Cancer
1 trial -
D5336C00001
AstraZeneca AB
Triple Negative Breast Cancer
1 trial -
D533AC00001
AstraZeneca AB
Unresectable or Advanced Melanoma
1 trial -
D6132C00001
AstraZeneca AB
First-line patients with extensive disease small-cell lung cancer (SCLC)
1 trial -
D6186C00001
AstraZeneca AB
Advanced Non-Small Cell Lung Cancer
1 trial -
D6187C00001
AstraZeneca AB
Non-Small Cell Lung Cancer
1 trial -
D6405C00002
AstraZeneca AB
Chronic Kidney Disease and Albuminuria
1 trial -
D6405C00002
AstraZeneca
Chronic Kidney Disease
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.